MedTrace Logo

Epidemiology of Cutaneous Leishmaniasis in Niger, Mali, Togo : Mapping of Clinical Cases, Species, Reservoirs and Vectors of the Disease

NCT06692985 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 270

Last updated 2024-11-20

No results posted yet for this study

Summary

Cutaneous leishmaniasis is a neglected tropical disease caused by parasites belonging to the genus Leishmania. This infection can cause skin and sometimes mucous membrane lesions with significant damage. LC has been little studied in sub-Saharan Africa where its incidence is probably underestimated, especially in West Africa. Leishmania major is almost the only isolated species in this region, although recent data suggest the existence of other species, such as L. enrietti. It is said that CL is only present in the arid areas of Africa, but recent outbreaks in wetlands and forests tend to contradict this theory. Due to the lack of availability of the PCR method, the diagnosis of LC in West Africa, especially in Mali, is rarely confirmed. Treatment options are also scarce and their effectiveness is poorly documented. The objectives of this study are to map the occurrence of LC cases with molecular biology confirmation in Niger, Mali and Togo; to determine the different species involved in human cases; evaluate the different treatment options available.

Conditions

  • Cutaneous Leishmaniasis

Interventions

OTHER

Clinical and epidemiological data

Collection of clinical and epidemiological data on day 0

OTHER

Parasitological samples

Parasitological samples : smear for on-site analysis and swabs to be sent to the Cayenne Hospital for PCR at day 0

OTHER

Assessment of clinical course and response to treatment

Follow-up visit with assessment of clinical course and response to treatment at M6

OTHER

DLQI questionnaire

DLQI questionnaire at M6

Sponsors & Collaborators

  • Centre Hospitalier de Cayenne

    lead OTHER

Principal Investigators

  • Romain BLAIZOT, MCU-PH · Centre Hospitalier de Cayenne (CHC)

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2024-03-01
Completion
2024-03-01

Countries

  • Mali
  • Niger
  • Togo

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06692985 on ClinicalTrials.gov